The COVID‑19 pandemic brought clinical trials to a grinding halt, forcing researchers and pharmaceutical sponsors to rethink the traditional trial model. Suddenly, participant recruitment and retention became daunting tasks as social distancing and l...
Markdown supported · ⌘↵ to post
No responses yet.